Watch IMRX. Know when insiders buy.
One email the day a filing lands. Free.
IMRX
Immuneering Corp
4.46
+0.01 +0.22%
USD · close Sep 17
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
43
WATCH · shorts 43
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $115.7MP/E —DIV YIELD —FCF YIELD -49.26%REV TTM —NET INCOME −$57.3MNET CASH —52W 3.92 – 9.26SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$19M | −$17.3M | — | -0.27 | −$16.5M | $27K | −$16.5M | Aug 5 |
| Q1 2026 · Mar 31 | — | — | — | −$15.3M | −$13.5M | — | -0.21 | −$18.4M | $80K | −$18.5M | Aug 5 |
| Q4 2025 · Dec 31derived | — | — | — | −$13.8M | −$11.6M | — | -0.07 | −$9.8M | $124K | −$10M | Mar 6 |
| Q3 2025 · Sep 30 | — | — | — | −$15.4M | −$15M | — | -0.38 | −$12M | $7K | −$12M | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$14.8M | −$14.4M | — | -0.40 | −$9.4M | $2K | −$9.4M | Aug 5 |
| Q1 2025 · Mar 31 | — | — | — | −$15.5M | −$15M | — | -0.42 | −$14.1M | $9K | −$14.1M | Aug 5 |
| Q4 2024 · Dec 31derived | — | — | — | −$18.6M | −$18.1M | — | -0.59 | −$14.5M | $9K | −$14.5M | Mar 6 |
| Q3 2024 · Sep 30 | — | — | — | −$15.3M | −$14.6M | — | -0.49 | −$13.5M | $5K | −$13.5M | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$14.9M | −$14.1M | — | -0.47 | −$11.5M | $33K | −$11.6M | Nov 12 |
| Q1 2024 · Mar 31 | — | — | — | −$15.3M | −$14.3M | — | -0.49 | −$15.5M | $37K | −$15.5M | Nov 12 |
| Q4 2023 · Dec 31derived | $0 | — | — | −$16.3M | −$15.1M | — | -0.52 | −$11.8M | $171K | −$11.9M | Mar 20 |
| Q3 2023 · Sep 30 | $0 | — | — | −$13.9M | −$12.6M | — | -0.43 | −$12M | $57K | −$12.1M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$59.4M | −$56M | — | -1.27 | −$45.3M | $142K | −$45.5M | — | — |
| FY2024 · to Dec 31 | — | — | −$64.1M | −$61M | — | -2.04 | −$55M | $85K | −$55.1M | — | — |
| FY2023 · to Dec 31 | $0 | — | −$58.4M | −$53.5M | — | -1.88 | −$49M | $343K | −$49.3M | — | — |
| FY2022 · to Dec 31 | $317K | 50.1% | −$51.7M | −$50.5M | -15937.3% | -1.91 | −$44.1M | $742K | −$44.8M | — | — |
| FY2021 · to Dec 31 | $2.1M | 44.6% | −$33.9M | −$33.5M | -1612.3% | -2.46 | −$30.9M | $61K | −$30.9M | — | — |
| FY2020 · to Dec 31 | $2.3M | 44.6% | −$17.1M | −$17M | -737.2% | -3.44 | −$14.6M | $53K | −$14.7M | — | — |
Every number comes from Immuneering Corp's own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.